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Cell therapy strategies and improvements formuscular
dystrophy
M Quattrocelli1, M Cassano1, S Crippa1, I Perini1 and M Sampaolesi*,1,2
Understanding stem cell commitment and differentiation is a critical step towards clinical translation of cell therapies. In past
few years, several cell types have been characterized and transplanted in animal models for different diseased tissues, eligible
for a cell-mediated regeneration. Skeletal muscle damage is a challenge for cell- and gene-based therapeutical approaches,
given the unique architecture of the tissue and the clinical relevance of acute damages or dystrophies. In this review, we will
consider the regenerative potential of embryonic and somatic stem cells and the outcomes achieved on their transplantation
into animal models for muscular dystrophy or acute muscle impairment.
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Muscular dystrophies are a heterogeneous group of inherited
diseases, primarily characterized by severe and chronic
skeletal muscle degeneration. Duchenne muscular dystrophy
(DMD) is the most severe disease among similar dystrophic
diseases and is caused by frame-shift deletions, duplications,
or point mutations in dystrophin gene. Patient mobility is highly
affected, usually resulting in wheelchair dependency, and
death occurs due to respiratory or cardiac failure.1,2
New strategies for the treatment of this disease are
currently being investigated and are categorized by two
approaches: endogenous activation and exogenous delivery
(Figure 1). The first strategy consists of re-activating
endogenous cells to achieve muscle hypertrophy, counter-
acting the mass/force loss in inflamed fibres. To reach this
goal, a growing range of small molecules or recombinant
proteins has been tested, including insulin-like growth factor 1
(IGF1),3,4 MagicF15 or valproic acid.6 The second strategy, on
the contrary, relies on exogenous tools (gene and/or cell
therapies) to improve muscle regeneration, thus providing
new, functional fibres to the dystrophic muscle. Gene therapy
targets the genetic defects, attempting to overcome patholo-
gical mutations by providing the muscle with the correct form
of the gene7 or by correcting the splicing through the exon-
skipping vectors8,9 or drugs, such as PTC124.10 Cell therapy,
however, is based on stem cell-driven muscle regeneration,
by systemic or local injections.
This review will focus on in vivo cell therapy strategies and
improvements in the treatment of sarcoglycan/dystrophin
complex-related dystrophies, such as Duchenne or limb-
girdle muscular dystrophies.
Animal Models for Sarcoglycan/Dystrophin
Complex-Related Muscular Dystrophies
Sarcoglycan/dystrophin complex-related muscular dystro-
phies are caused by disruption of the sarcoglycan–dystrophin
complex that normally anchors the actin fibres to the
sarcolemma, generally resulting in chronic muscle wastage,
progressive fibrotic infiltrations and force decrease.Moreover,
cardiac involvement is often described, in terms of chronic
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dilatative cardiomyopathy, scar infiltrations, aneurisms and
repeated microinfarctions.
DMD is the most severe form and it is caused by frame-
shift mutations or huge deletions in the dystrophin gene. It is
one of the largest gene in the human genome and encodes
a 14-kb mRNA. In this type of dystrophy, the protein is
completely or partially lost. A less severe phenotype is
observed in Becker dystrophy, in which mutations still affect
the dystrophin gene, but myofibres retain a truncated and
low-active isoform of the protein. Some forms of limb-
girdle muscular dystrophy (LGMD2) are also caused
by mutations in sarcoglycan complex proteins, for example,
a- or b-sarcoglycan (asg or bsg) depletion, and can result in
severe pathological phenotypes.
Several animal models have been developed to study
muscular dystrophies, particularly for DMD and LGMD2. The
most widely used model for dystrophy is the mdx mouse that
carries an X-linked mutation in the dystrophin gene, thus
mimicking, at least in principle, the DMD genotype in humans.
In mdx mice, the effects of degeneration are less severe,
mainly due to the presence of relatively high numbers of
revertant fibres (1–3%)11 and an upregulation of utrophin.
Utrophin is a smaller analogue of the dystrophin and may
account for the partial compensatory effect on muscle
wastage.12,13
Recently, it has been demonstrated that mdx satellite
cells undergo telomere erosion, which may also contribute to
the inability of these cells to continuously repair DMDmuscle.
It is possible that muscle stem cells or myogenic progenitors
that maintain telomerase activity until late passages, may
contribute in part to the muscular regeneration, that provides
mdx mice with a normal life span.14
Feasible models of LGMD2 are a-sarcoglycan- and
b-sarcoglycan-knockout mice. These mice are very close to
the human phenotype of LGMD2D and LGMD2E, respec-
tively, as they show chronic skeletal muscle degeneration
and, in the case of bsg-KO mice, dilatative cardiomyo-
pathy.15,16 In a-sarcoglycan-KO mice, asg gene is disrupted
through a neomycin cassette insertion between exons 1 and
9, through homologous recombination of the flanking regions.
Similarly, in the b-sarcoglycan-KO mice, the region encom-
passing exons 3–6 of bsg gene is disrupted. LGMD mice are
considered a better animal model than mdx mice because of
their lack of revertant fibres, which often render mdx mice-
related results controversial.17
Canine models of DMD are being also extensively
studied.18,19 The larger fibres in canine muscles mimic the
human dystrophy effects better than that of the mouse. At
present, there are two major colonies of dystrophic dogs all
over the world, bearing the same mutation in different genetic
backgrounds; a colony of Golden Retrievers and one of
Beagle dogs. These animals are both derived through cross-
breeding of a naturally born, affected founder because
transgenic creation would be unethical in these animal
models. The mutation lies in intron 6 of dystrophin gene and
results in aberrant splicing that causes a premature transcrip-
tion stop codon. Dystrophic dogs, from both varieties, show
extremely affected motility, posing, salivation, severe chronic
scar infiltrations and skeletal muscle degeneration. In these
animals, revertant fibres are also almost undetectable, thus
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Figure 1 Combining endogenous activation and exogenous delivery to enhance muscle regeneration. Currently, two therapeutical approaches are investigated for the
regeneration of the skeletal muscle: the endogeneous activation of physiological repair potential, such as targeting of satellite, circulating or perycite cells through small
molecules, or the exogenous delivery of stem cells or genetic tools, such as antisense oligonucleotides (ODNs), drugs (PTC124) or viral vectors. M-SP, muscle side
population; BM-SP, bone marrow side population; BMSCs, bone marrow-derived stem cells; MABs: mesoangioblasts; MADS, multipotent adipose-derived stem cells; iPS,
induced pluripotent stem cells, not yet injected in animal models for muscular dystrophy; ESCs, embryonic stem cells
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providing a good model to analyze regeneration effects of cell
and genetic therapies.
Cell Models for In Vivo Skeletal Muscle Regeneration
To date, the only clinical treatments for muscular dystrophy
are steroid administration and non-invasive intermittent
positive pressure ventilation. These treatments result in
amelioration of symptoms and improved quality of life.20
Despite the benefits of slightly longer lifespan, alleviation of
pain and surgical management of scoliosis, this therapy
showsmany side effects, such as weight increase, and has no
real beneficial effects on skeletal muscle architecture and
force.21 Thus, cell therapy represents a theoretical valuable
alternative. The main goal of cell therapy is to directly
regenerate wasted, adult muscle fibres through systemic or
targeted injection of stem cells, which function to blockmuscle
loss and restore, at least partially, the normal muscular
activity. It is currently a difficult task to conjugate high
efficiencies in cell motility, homing, engraftment and differ-
entiation into the complex environment of a severely
inflammed and degenerated muscle. Several cell models
have been tested in vivo, with diverse results (Table 1). Three
main classes of stem cells with a myogenic differentiation
potential have been considered for cell therapy protocols in
preclinical studies for the treatment of muscular dystrophy:
(i) embryonic stem cells (ESCs) and induced pluripotent stem
cells (iPSs); (ii) bonemarrow-derived stem cells (BMSCs) and
circulating progenitors; and (iii) local myogenic-committed
progenitors.
ESCs and iPS cells. Embryonic stem cells (ESCs) are
generally considered the most promising natural source of
pluripotent cells for cell therapy, but few attempts have been
reported in muscle regeneration and efficiencies are still
quite low. Importantly, ethical issues around their pro-
curement and use, such as blastocyst disgregation and
oocyte requirement, have raised a lot of concerns and limited
the use of human ESCs (hESCs) for research purposes in
several countries.
The critical step in using ESCs resides in cell conditioning
before engraftment, a necessary step that increases the
differentiation rate towards myogenesis and avoids teratoma
formation. A heterogeneous suspension, derived from a co-
culture of male embryoid bodies and female freshly isolated
dystrophic satellite cells, has been demonstrated to produce
few chimeric, dystrophin-positivemyofibres in injuredmuscles
of female mdx mice.22 Promising results have been obtained
with hESCs, cultivated to enrich in mesenchymal precursors.
The CD73þ NCAMþ sub-fraction was able to differentiate
into myotubes in vitro and, remarkably, to regenerate up to
7% of injured skeletal muscle in immunodeficient mice.23
Recently, another strategy has been developed using paraxial
mesoderm progenitors that are isolated from differentiating
ESCs. The PDGFRaþ /Flk1 fraction of Pax3-induced,
embryoid body-derived cells shows activation of myogenic
transcription factors in vitro and good differentiation in
dystrophinþ fibres on transplantation into both cardiotoxin-
injured and dystrophic muscle. Injected mice also show an
amelioration of the contractility force. In this case, intra-arterial
administration of cells resulted in higher engraftment than
intravenous injection.24 In another study, paraxial mesoderm
progenitors were isolated as PDGFRaþ /VEGFR2þ cells,
which also have been successfully tested in cardiotoxin-
injured quadriceps of KSN nude mice.25
A new source of pluripotent cells comes from the
reprogramming of adult murine or human somatic cells, by
means of pluripotency transcription factor expression. Human
iPS (induced pluripotent stem, hiPS) cells are reprogram-
med from differentiated, adult cells, such as fibroblasts, to an
ES-like status, by retroviral-mediated transduction of
OCT4, SOX2, KLF4 and, even if dispensable, c-MYC.26–28
As hiPS cells are created by reprogramming adult cells into
a flexible, embryonic-like state, they have been claimed as
alternative pluripotent cells to overcome the ethical issues
regarding the use of ESCs. However, some reservations exist
regarding the in vivo safety of hiPS cells, which must be
addressed in the future. Recently, a wide range of disease-
specific hiPS cells has been generated from patients with
various Mendelian or complex diseases, including Duchenne
and Becker muscular dystrophy.29 These cells could repre-
sent a greater advancement in terms of plasticity and life span,
in comparison with other cell lines tested to date. Moreover,
these DMD- or BMD-specific hiPS cells show the same
genetic background of the donor, thus representing a good
model for in vitro drug testing and, if genetically corrected,
a suitable cell line for extensive skeletal muscle repair.
Bone marrow-derived and circulating progeni-
tors. Mesenchymal stem cells have been tested in acute
and chronic muscle wastage, but results are still controver-
sial. After bone marrow transplantation (BMT) in dystrophic
mice, BMSCs are able to migrate and contribute to the
formation of new Myf5þ fibres through repeated rounds of
inflammation and regeneration, which is typical of the mdx
mouse muscles.30 In humans, the clinical case of a young
DMD patient (deletion of the exon 45 in the dystrophin gene)
has been reported, which 12 years after BMT, showed donor
nuclei fused to 0.5% of dystrophic myofibres.31 Real-time
RT-PCR analysis detected a small amount of a truncated,
in-frame isoform of dystrophin, lacking exons 44 and 45, and
trace amounts of the wild-type gene (0.0005%), although a
direct correlation between the BMT-derived nuclei and the
dystrophin isoform expression was missing. In addition,
human mesenchymal stem cells isolated from synovial
membrane of adult donors, on intramuscular delivery into
tibialis anterior of mdx mice, efficiently produce new, func-
tional myofibres, without any sign of fusion. These cells also
contribute to the long-term satellite cell population and
restore mechano growth factor (MGF) expression in treated
muscles.32 The myogenic potential of these cells seems
to be strongly related to the microenvironment surrounding
the delivered cells because when injected systemically in
dystrophic mice, they are observed in almost all tissues.
Given the broad availability of the source, human multi-
potent adipose-derived stem cells (hMADS) have been
investigated as a possible alternative for muscle regeneration.
hMADS are CD44þ , CD90þ and CD105þ , confirming their
mesenchymal lineage. Once injected intramuscularly into
tibialis anterior of immunocompetent and immunosuppressed
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mdxmice, they fuse with host fibres, resulting, 6 months later,
in a large number of chimaeric myofibres expressing human
dystrophin. Interestingly, no differences are reported between
immuno-competent and immuno-suppressed hosts and it
also seems that hMADS significantly reduce necrosis in the
dystrophic muscle.33 These promising results have since
been enhanced by priming the adipose-derivedmesenchymal
cells by co-culturing with myoblasts34 or forced MyoD
expression.35
A sub-population of circulating, haematopoietic stem cells
expressing CD133, which constitutes another interesting and
easily isolatable cell pool, has been reported to express early
myogenic markers.36 Intramuscular or intra-arterial injection
of genetically corrected CD133þ progenitors, isolated from
both peripheral blood and muscles of DMD patients, results
in a significant recovery of muscle morphology, function and
re-expression of human dystrophin in scid/mdx mice.37
In contrast, several studies have reported of absent or
incomplete muscle repair by mesenchymal or haematopoietic
stem cells. On being intravenously injected into a mouse
model for LGMD2F (mice lacking d-sarcoglycan), bone
marrow side population cells engraft and fuse into skeletal
fibres, but do not restore d-sarcoglycan expression.38 Green
fluorescent protein-positive bone marrow (GFPþ BM) cells,
delivered through retro-orbital injection, fuse with B3% of
fibres in the tibialis anterior of treated mdx mice, but almost
no dystrophin expression is detected in GFPþ myofibres.
However, where dystrophin is detected, its expression is
spatially more limited than in revertant fibres.39 These data
have been confirmed in another study, in which it has been
demonstrated thatX80% of BM-derivedmuscle-incorporated
nuclei in the transplanted dystrophic mouse are ‘silent’. In-
corporated nuclei fail to express myogenic factors, including
dystrophin, and this ‘silencing’ is still retained even in the
presence of strong chromatin-remodelling agents, such as
50-azacytidine.40 It has also been demonstrated that haema-
topoietic cell transplantation (HCT) alone result neither in any
skeletal fibre regeneration nor in expression of dystrophin or
other muscle genes.41 Nevertheless, an interesting role for
HCT in muscle regeneration may come from immunoto-
lerance effects towards allogeneic myoblast engraftment.
DMD dogs have been successfully treated using both
peripheral HCT and freshly isolated myoblasts from the same
healthy donor. Donor myoblast-related dystrophin expression
increased up toB7% of wild-type levels and was maintained
for at least 24 weeks, without any pharmacological immuno-
suppression.42
Finally, bone marrow-derived multipotent adult progenitor
cells (MAPCs) were observed to durably repair muscles in
ischaemic limbs, by efficient revascularization of necrotic
tissues.43
Local myogenic-committed progenitors. Satellite cells
are quiescent unipotent myoprecursors, located between
the fibre and the basal lamina; during embryogenesis, they
form during the second wave of myogenesis and, after
contributing massively to the first post-natal muscle growth,
they stop proliferating and reach their niche.44 They can also
be re-activated on muscle damage, re-entering cell cycle and
contributing to the formation of new muscle fibres.45 Given
their natural commitment, it’s easy to imagine satellite cells
as a major candidate for muscle regeneration in muscular
dystrophies. On single fibre transplantation into radiation-
ablated mdx tibialis anterior, donor satellite cells multiply and
expand, re-populating the satellite cell pool and differentiate
into functional myofibres.46 Pax7þ CD34þ GFPþ satellite
Table 1 Stem cell types for the treatment of chronic or acute skeletal muscle damage
Stem cell types Markers Animal models
Muscle
damage Delivery Ref.
hESCs CD73+/CD56+ (sub-fraction) SCID/Beige mice Acute Intramuscular 23
ESCs Pdgfra+/Flk1 (sub-fraction) Rag2/gc/ mice/mdx mice Acute/chronic Intra-arterial4
intravenous
24
Pdgfra+/Vegfr2+ (sub-fraction) KSN nude mice Acute Intramuscular 25
hBMSCs VIMENTIN+/CD44+ NMRI nu/ mice/mdx mice Acute/Chronic Intramuscular 32
hMADS CD44+/CD90+/CD34/
HLA-DR/HLA-Ilow
mdx mice Acute/Chronic Intramuscular 33
Human circulating
CD133+ progenitors
CD133+/CD34+/CD45+/CD90+ scid/mdx mice Chronic Intramuscular/
intra-arterial
37
BM-SP cells Cd34/low/Cd117+/Sca1+ LGMD2F (Sgcd2/) mice Chronic Intravenous 38
Satellite cells Cd34+/Pax7+/Cd31/Sca1 mdx nu/ mice Chronic Intramuscular 47
Cd34+/Integrina+ (clonal level) NOD/SCID mice Acute (resident
satellite cell
withdrawal)
Intramuscular 48
SMPs CD45/Sca1/Mac1Cxcr4+/
b1integrin+
mdx mice Acute Intramuscular 49
Muscle-SP cells Sca1+/Cd45+/Abcg2+ mdx5cv mice Chronic Intra-arterial 54
Sca1+/Abcg2+/Syndecan4+/Pax7+ Rosa26 mice/mdx mice Acute/chronic Intramuscular 55
MABs (human,
canine, murine)
Pdgfra+/Pdgfr b+/Ng2+/Alp+ Sgca/ mice/GRMD
dogs/scid/mdx mice
Chronic Intra-arterial 57–59
Myoendothelial
progenitors
Cd56+/Cd34+/Cd144+ scid mice Acute Intramuscular 61
Abbreviations: hESCs, human embryonic stem cells; ESCs, embryonic stem cells; hBMSCs, human bone marrow-derived stem cells; hMADS, human multipotent
adipose-derived stem cells; BM-SP, bone marrow side population; HSCs, haematopoietic stem cells; SMPs, skeletal muscle precursors; Muscle-SP, muscle side
population; MABs, mesoangioblasts
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cells, isolated from Pax3GFP/þ mice diaphragms, have also
been demonstrated to be a good cell model for mdx irradia-
ted muscle treatment, resulting in the restoration of dystrophin
expression in many skeletal fibres and contributing to the
resident satellite compartment.47 Injections were adminis-
tered intramuscularly and, notably, two major problems
arose; satellite cells have a very low migration capability
and, furthermore, cells showed impaired engraftment
capability when expanded in vitro, even if for few days.47
To test the regeneration capability of satellite cells at a
clonal level, single-cell dilutions of CD34þ integrinaþ
luciferase-expressing satellite cells were injected into the
skeletal muscle of a NOD/SCID mouse depleted of resident
satellite cells by 18Gy irradiation. It was shown by in vivo
imaging that a single satellite cell can reconstitute the satellite
compartment and, on further damage, can rapidly re-enter a
new proliferation wave, generating new myofibres.48
Recently, interesting findings resulted from a prospective
isolation of skeletal muscle precursors (SMPs), consisting of
a CD45 Sca1 Mac1 Cxcr4þ b1-integrinþ subset within
the endogenous satellite compartment. When injected into
cardiotoxin-injured muscles in immunodeficient mdx mice,
SMPs robustly contributed to muscle regeneration (up to
94%) by fusing with pre-existing fibres or stimulating de novo
myogenesis. Muscle histology and contractile force in treated
mice were significantly better than those in untreated mice.
Furthermore, SMPs contributed greatly to the endogenous
satellite population, undergoing new cycles of re-activation on
subsequent induced damage.49 However, as freshly isolated
SMPs were injected, without in vitro expansion, the migration
capability remains restricted in the areas surrounding the
intramuscular injection site.
One of the major concerns about satellite cells is that,
probably, they are not a homogeneous population. As argued
by Collins et al.,46 the variable engraftment rate of satellite
cells from a singlemyofibre transplantation could be due to the
functional heterogeneity of the satellite cell pool and of their
niche of origin. Satellite cell heterogeneity is still a contentious
issue and has been extensively reviewed in several
studies50,51 and is still open for debate.52
Muscle side population (SP) cells are defined as Sca1þ
CD45þ cells, able to rapidly efflux the Hoechst dye 33342,
and are being investigated as potential myogenic progenitors.
They are associated with the muscle vasculature and are
spontaneously committed towards the haematopoietic line-
age. On co-culture with myoblasts, they can form myotubes
in vitro and, if injected intramuscularly into crushed tibialis of
a scid/bg immunodeficient mouse, can give rise to up to 1%
of regenerating fibres.53 The efficiency of SP-mediated
muscle regeneration has been increased to 5–8% by injection
into the femoral artery ofmdx5cv DMD mice, resulting in Pax7
and desmin expression by donor cells, after extravasation and
recruitment to inflammation sites.54 Impressive results have
been obtained with the identification of a rare subset (0.25%)
of SP cells, characterized by both satellite- and SP-related
markers, such as Sca1þ /ABCG2þ /Syndecan4þ /Pax7þ ,
and found in the typical satellite compartment, under the
basal lamina. Once sorted from the mononuclear fraction of
the hind limb, they can grow in association with single muscle
fibres and can robustly undergo myogenic differentiation
in vitro. On intramuscular injection in the presence of 1.2%
BaCl2, these satellite-SP cells have been shown to efficiently
compete with endogenous satellite cells in regenerating the
wild-type muscle. Injected cells resulted in 30% fibre
regeneration and, strikingly, in up to 75% reconstitution of
the endogenous satellite cell pool. The newly generated
satellite cells were able to undergo new rounds of proliferation
and muscle repair on subsequent injuries. Furthermore, the
same long-term effects have been proven through injections
into dystrophic mdx4cv tibialis anterior muscles, producing up
to 70% regenerating fibres.55 However, BaCl2-induced
muscle damage is not a widely used and accepted regenera-
tion model, and this must be taken into consideration when
interpreting these findings.
Recently, a new type of vessel-associated muscle-derived
stem cells has been investigated as a suitable potential model
for chronic muscle therapy, namely mesoangioblasts (MABs).
They can be isolated from the dorsal aorta of E9.5 embryo56 or
from adult skeletal muscle of mice, dogs and humans.57–59
MABs are CD34þ , Sca1þ , PDGFRaþ , PDFGRbþ , NG2þ
and ALPþ , thus supporting the idea that they are a sub-group
of the pericytic population.60 They show high proliferation
rates in vitro, without transformation potential, and display,
in in vitro and embryonic chimaera systems, multipotent
differentiation capability towardsmyogenic, osteogenic, chon-
drogenic and adipogenic lineages. On intra-arterial injection
into inflammated muscles of asg-KO mice or DMD Golden
Retriever dogs, they are capable of consistently regenerating
(up to 50%) the muscle architecture, sarcoglycan/dystrophin
expression and electrophysiological properties of wasted
dystrophic muscle.57,58 Similarly, good results have been
achieved through human MAB transplantation into scid–mdx
immunodeficient dystrophic mice.59
Treatment of dogs with MABs resulted in very good and
long-term results in some animals, in terms of general motility
restoration and whole muscle regeneration, whereas other
animals did not show a good engraftment and any clinical
improvement.58 This confirms the general idea that back-
ground variability in dystrophies in larger organisms, such as
dogs or humans, has to be evaluated for effective cell
therapies.
Furthermore, another class of myogenic precursors has
been isolated from endothelial population of adult human
muscle, through FACS-mediated prospective isolation of
CD56þ CD34þ CD144þ cells. These myoendothelial pro-
genitors, on injection into injured muscle of scid mice can
achieve muscle engraftment and fibre neo-formation at an
higher degree than CD56þ canonical myoprecursors.61
Cell Conditioning and Priming
To increase engraftment specificity and differentiation poten-
tial, cell transplantation can be combined with pre-injection
cell conditioning or with genetic manipulation.
Cell migration limitations are often a major cause of low
engraftment efficiencies in skeletal muscle, which is a very
complex tissue with severely limited cell motility, particularly
in the presence of large fibrotic or necrotic areas. Thus, some
attempts have been made to assist migration by condition-
ing cells with migration-enhancing soluble factors or by
Cell therapy for muscular dystrophy
M Quattrocelli et al
1226
Cell Death and Differentiation
overexpressing commiting/mobilizing proteins before apply-
ing them to the degenerated muscle.
A lot of interest has been shown in Notch signalling, as a
potential enhancer of myogenic commitment. Rat BMSCs,
transfected with a plasmid for the intracellular domain of
Notch1 (NICD) and injected locally or intravenously into
injured muscles of rats or nude mice, account for a very high
level of regenerating fibres (up to 89%).62 Given that NICD is
the active signalling form of the receptor, it could be possible
that finer genetic tools to activate Notch signalling could
enhance myogenesis by donor cell injection, although
recently it has been demonstrated that a temporal switch
from Notch toWnt3a signalling activation is necessary during
normal adult myogenesis.63
Encouraging in vivo results have come from cell therapy
experiments involving soluble factor-dependent cell condi-
tioning. Hmgb1, a cytokine secreted by activated macro-
phages and monocytes, is able to increase the recruitment of
MABs out of the vessels into the muscle. Heparin–Sepharose
beads, loaded with Hmgb1 and injected into the femoral
artery, were shown to promote the trans-endothelial migration
of intra-arterial-injected embryonic MABs into non-injured
tibialis anterior of wild-type mice.64 Pre-treatment of MABs
with mobilization cytokines, such as SDF1 and TNFa, highly
increaseMAB homing into dystrophic muscle of asg-nullmice,
thus reducing approximately 50% the aspecific homing into
filter organs. Their regenerative effect was magnified by
TNFa priming and a4-integrin overexpression.65 Furthermore,
improving the angiogenic potential in necrotic areas could
help cell therapy. For example, tendon fibroblasts expressing
placenta growth factor (PIGF, an angiogenic factor) and
matrix metalloproteinase 9 (MMP9), injected intramuscu-
larly into aged asg-KO mice, result in a dramatic increase
in the extension of regenerated dystrophinþ muscle areas
after intra-arterial delivery of wild-type MABs.66 Such results
corroborate the idea that a deeper knowledge of cytokines
and angiogenic factors regulating the inflammation-depen-
dent recruitment of myoprecursors will serve to improve the
benefits mediated by cell therapy.
Genetic Manipulation for Autologous Cell Therapy
Correction of the dystrophic genotype in the transplanted
cells could allow the usage of autologous cells, instead of
heterologous wild-type cells, thus avoiding immunosuppres-
sive drugs.
A widely used strategy relies on lentiviral transduction of
muscle-regenerating cells to allow integration and expression
of the disrupted gene. To correct DMD, several alternatives of
the dystrophin gene (which is too long to be introduced in a
lentiviral vector) exist, such as micro- or mini-dystrophin.
These are shorter isoforms of the native protein, which retain a
partial functionality, thus providing, in principle, a possible
molecular rescue on differentiation towards newly formed
myofibres. mdx5cv mice, injected intravenously with auto-
logous muscle-SP cells that were previously transduced with
human micro-dystrophin (hmDYS)-expressing lentiviruses,
show some skeletal fibres positive for the human version of
the lacking protein.67 Similarly, very good results came from
transplantation of hmDYS-transduced human pericytes into
mdx–scidmice.59 In GRMD dog treatment, autologousMABs,
transduced with human micro-dystrophin, induced a quite
widespread expression of dystrophin and other proteins of
the sarcoglycan complex in analyzed muscles and a partial
recovery of the histological architecture. However, treated
dogs had poorly restored general motility and force.58 These
results may support the idea that, especially in higher
organisms, mini- or micro-genes are not so feasible, or, at
least, show highly variable and only short-term effects.
Genetic correction can be addressed also for treatment of
other genetic defects resulting in dystrophy, as when asg-KO
MABs, carrying a lentiviral asg cDNA construct under a
constitutive promoter, are injected into LGMD2D mice, there
is extensive fibre regeneration, mobility and muscle force
recovery.57
Conclusions and Perspectives
Stem cell-based therapy is the most attractive approach for
the treatment of DMD and other muscular dystrophies, and
research in this direction has moved rapidly in past few years.
Experiments in small and large animal models are paving the
way for clinical experimentation, but it would be imprudent to
predict a ‘cure’ from these first attempts. Nevertheless,
several clinical trials have been started or planned, involving
myoblast or perycyte injection fromHLA-matched donors and,
given the growing variety of possible myogenic progenitors in
literature, the number will increase during the near future.
Other clinical trials are focusing on gene- or antibody-based
strategies, such as adeno-associated viruses carrying
g-sarcoglycan or m-dystrophin and antibody-triggered myo-
statin blockade.21
Furthermore, encouraging results have come from clinical
trials related to exon-skipping technology. Specific exons
carrying mutations can be skipped by antisense oligonucleo-
tides administration to restore the reading frame and result in
the production of internally deleted, but functional dystrophin.
Recently, two clinical trials involving two different drugs, AVI-
4658 (developed by the MDEX Consortium, United Kingdom
and manufactured by AVI BioPharma, Bothell, WA, USA) and
PRO051 (developed by University of Leiden, The Nederlands
in collaboration with Prosensa B.V.), were performed on
Duchenne patients. In both trials, biopsy data showed that
injections of antisense oligonucleotides, to skip exon 51, into
dystrophic muscles, successfully induced new dystrophin
production, with no adverse events. These pioneering studies
are now followed by randomized controlled trials of systemic
therapies both in The Netherlands and the United Kingdom.
Therefore, it is reasonable to expect encouraging results
that may also drive a combination of the stem cell- and gene-
based therapies. It is critical to better understand the
biological properties of stem cells and their paracrine role in
the treatment of muscular diseases, to realize the potential
positive effects of these new cures.
The scientific community largely accepts the presence of
adult stem cells in all tissues but their origin is still contro-
versial. We and other authors suggest pericytes as a source
of stem cells present in skeletal and cardiac muscles.59,60
They are influenced by their surrounding when maintaining
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a specific cell commitment, although this has to be clarified
in pathological tissues.
Interestingly, other research groups have identified
mesenchymal cells as stem cells for all tissues,68 raising
questions regarding the possibility that the primary source of
cell plasticity is confined to the bone marrow. It could be
possible that cells move from bone marrow towards pericyte
compartment, to adopt a specific cell fate, influenced by local
niche. To further elucidate their origin, it is necessary to
generate transgenic animals to track endogenous stem cells
during muscle development and regeneration.
Despite the fact that current regulatory restrictions will defer
the clinical translation of new approaches, that are successful
in animal models, several trials have been started. Moreover,
the actual huge costs of GLP–GMP (good laboratory and
manufacture practice) stem cell technology limit the feasibility
of cell therapy treatment for patients affected by muscular
dystrophy. However, strategies to lower costs are being
investigated to develop treatments that are available for large
numbers of patients. In conclusion, it is critical to better
understand the biological properties of stem cells and their
paracrine role in the treatment of muscular diseases, to realize
the potential positive effects of these new cures. Therefore, it
is reasonable to expect encouraging results from the on-going
trials that may also drive a combination of stem cell- and gene-
based therapies for the treatment of muscular dystrophies.
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